Advanced glycation end products, their receptors and diabetic angiopathy

Diabetes and Metabolism

Volumn 27, Issue 5 I, 2001, Pages 535-542

  Wautier, J L ^a   Guillausseau, P J ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

Author keywords

Advanced glycation end products; Diabetic angiopathy; Glycoxidation; Hyperglycemia; Receptor for advanced glycation end products (RAGE)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE;

BLOOD VESSEL TONE; BLOOD VESSEL WALL; CELL ACTIVATION; CHRONIC DISEASE; CYTOKINE PRODUCTION; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG MECHANISM; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; MONOCYTE; NONHUMAN; PROTEIN BINDING; REACTION ANALYSIS; REVIEW;

ANIMALS; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; RECEPTORS, IMMUNOLOGIC;

EID: 0035153678     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. The effect of intensive treatment of diabetes on the development and long-term complications in insulin-dependent diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
3. Activation of RAGE: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
4. Diabetes, advanced glycation end products and vascular disease
5. Aspects physiopathologiques de l'angiopathie diabétique
6. ε (carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions
7. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients
8. ε (carboxymethyl) lysine in human tissues in diabetes and aging
9. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process
10. ε (carboxymethyl) lysine protein adducts is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction
11. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
12. Nutritional and toxicological aspects of the Maillard browning reactions in foods
13. Exogenous advanced glycosylation end products induce complex vascular dysfunctions in normal animals: A model for diabetic and aging complications
14. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs) novel inhibition of post-Amadori glycation pathways
15. Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation
16. Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo
17. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats
18. Cellular receptor for advanced glycation end products. Implication for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
19. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats
20. The human and rat recombinant receptors for advanced glycation end products have a high degree of homology but different pharmacokinetic properties in rats
21. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S 100/calgranulin polypeptides
22. ε (carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signalling pathways and modulate gene expression
23. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule 1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes
24. Modification of vitronectin by advanced glycation alters functional properties in vitro and the diabetic retina
25. Stucture elucidation of a senescence cross-link from extracellular matrix
26. ε -(carboxymethyl)lysine in human tissues in diabetes and aging
27. Role of the Maillard reaction in aging of tissue proteins
28. Accelerated age-related browning of human collagen in diabetes mellitus
29. Advanced glycosylation end products in continuous ambulatory peritoneal dialysis patients
30. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy
31. Advanced glycosylation end products in patients with diabetic nephropathy
32. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
33. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM
34. Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro
35. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: Decreased levels of heparan sulfate proteoglycan and laminin
36. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products
37. Free radicals in endothelial cell dysfunction
38. Advanced glycation end products in diabetic complications
39. Advanced glycosylation end products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes
40. Arteriolar reactivity in conscious diabetic rats. Influence of aminoguanidine treatment
41. Lipid advanced glycosylation: Pathway for lipid oxidation in vivo
42. Effect of aminiguanidine on lipid peroxidation in streptozotocin-induced diabetic rats
43. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells
44. Advanced glycation end products (AGES) on the surface of diabetic red cells bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGES and diabetic complications
45. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE
46. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall
47. Amyloid-beta peptide-RAGE interaction elicits neuronal expression of M-CSF: A proinflammatory pathway in Alzheimer's disease
48. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
49. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides
50. The S100 protein family: History, function, and expression
51. The receptor for advanced glycation endproducts (RAGE) is a cellular binding site for amphoterin: Mediation of neurite outgrowth and coexpression of RAGE and amphoterin in the developing nervous system
52. Blockade of amphoterin/RAGE signalling suppresses tumor growth and metastases
53. Blockade of RAGE suppresses periodontitis-associated alveolar bone loss in diabetic mice
54. Aminoguinidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat
55. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model
56. Maillard reaction products and their relation to complications in insulin dependent diabetes mellitus
57. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy
58. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
59. Increased collagen-likepentosidine levels and AGEs in early diabetic nephropathy
60. The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes
61. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy
62. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor
63. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas
64. Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of non enzymatic glycosylation
65. The effect of aminoguanidine on the blood-retinal barrier in streptozotocin-induced diabetic rats
66. Advanced glycosylation end products in patients with diabetic nephropathy
67. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes
68. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus
69. Effects of glycated albumin on mesangial cells: Evidence for a role in diabetic nephropathy
70. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats
71. Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells
72. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease
73. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycation end products is mediated via platelet-derived growth factor
74. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rats
75. Renoprotective effects of novel inhibitor of advanced glycation
76. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus
77. Relations between complications to type I diabetes mellitus and collagen-linked fluorescence
78. The role of glycation cross-links in diabetic vascular stiffening
79. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease
80. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
81. Suppression of accelerated atherosclerosis by the soluble receptor for advanced glycation end products